Partners of the biopharmaceutical consortium
CQDM’s mission is to fund the development of innovative tools and technologies that accelerate the discovery and development of safer and more effective drugs. To generate strong financial leverage and support high-risk high-reward projects, CQDM implemented a collaborative approach where Canadian and international partners fund biopharmaceutical research.
Together, they have already co-funded several projects of mutual interest. To date, partners have dedicated $30M in co-financing to biopharmaceutical research projects led by CQDM.
Biopharmaceutical research co-funding partners create synergies and promote collaborations between scientists and organizations across various disciplines. They pave the way to national and international contributions, while investing in research of mutual interest with CQDM.
Furthermore, biopharmaceutical research co-funding partners provide CQDM with complementary expertise, including such fields as:
- research in neurosciences, oncology and glycomics;
- company start-ups and funding;
- training of students and highly skilled personnel.
We are proud to have partnered with:
Accel-Rx is Canada’s health sciences accelerator supporting health innovation companies developing pharmaceuticals, medical devices and diagnostics. As seed investment specialists, Accel-Rx stewards early-stage companies selected from across the country to a level where they can successfully raise a Series A or equivalent financing. Through a unique growth platform that provides access to capital, industry connections, mentorship and customized guidance, the Accel-Rx formula is designed to stimulate Canada’s health sciences sector and ensure our innovations become competitive on a global scale. To learn more, visit us at www.accel-rx.com or follow us on Twitter @Accel_Rx.
Alsace BioValley is a cluster which federates in Alsace, all actors in life sciences and health (companies, research centers, hospitals, training institutions and universities). It is a unique and effective gateway to develop projects for bio-business, therapeutic innovation and employment. Alsace Bio Valley is also one of 71 clusters labelled by the French government in 2005 to support innovation excellence in France. Alsace BioValley accompanies the growth of players in the field of Life-Health in the territory of Alsace and beyond borders.
Created in July 2006, BioWin is the reference player in the field of health biotechnology and medical technologies in Wallonia (a region located South Brussels, in Belgium). The cluster federates all the Walloon stakeholders (companies, research centers and universities) involved in innovative R&D projects and/or trainings for the development of new products and services. BioWin has defined 4 strategic priorities: innovative R&D projects, building the skills that industry players need to succeed, international footprint of the cluster and its members, and the creation of technological platforms.
The Canadian Cancer Society (CCS) is a national, community-based organization of volunteers whose mission is the eradication of cancer and the enhancement of the quality of life of people living with cancer. Our vision is to create a world where no Canadian fears cancer.
We set ourselves apart from other cancer charities by taking a comprehensive approach against all cancers. We are always looking for new ways to prevent cancer, detect it early and treat it more successfully. That is why we are always ready to give people with cancer the help and support they need.
CCS is the cancer charity in Quebec that has the greatest impact. With some 40 offices and service centres across the province, CCS helps and supports more than two million people in Quebec each year. Thanks to the support of 300,000 donors and 30,000 volunteers in Quebec, it is able to prevent more cancers, fund more research projects and support more people living with cancer. Visit cancer.ca or call us at 1 888 939-3333.
Ontario Centres of Excellence (OCE) drives the commercialization of cutting-edge research across key market sectors to build the economy of tomorrow and secure Ontario's global competitiveness. In doing this, OCE fosters the training and development of the next generation of innovators and entrepreneurs and is a key partner with Ontario's industry, universities, colleges, research hospitals, investors and governments. A champion of leading-edge technologies, best practices and research, OCE invests in sectors such as advanced health, digital media and information communications, advanced manufacturing and materials, and clean tech including energy, environment and water. OCE through its Centre for Commercialization of Research (CCR), an initiative supported by the federal government, also acts as a catalyst which allows innovative businesses to grow and achieve sustainable commercial success and global competitiveness. OCE is a key partner in delivering Ontario's Innovation Agenda as a member of the province's Ontario Network of Excellence (ONE). Funded by the Government of Ontario, the ONE is Ontario's innovation system. The ONE is made up of regional and sector focused organizations designed to help Ontario-based entrepreneurs rapidly grow their companies, and create jobs.
The Canadian Institutes of Health Research (CIHR) is the Government of Canada's health research investment agency. CIHR's mission is to create new scientific knowledge and to enable its translation into improved health, more effective health services and products, and a strengthened health care system for Canadians. Composed of 13 Institutes, CIHR provides leadership and support to more than 12,600 health researchers and trainees across Canada.
Brain Canada is a national non-profit organization headquartered in Montreal, Quebec, that enables and supports excellent, innovative, paradigm-changing brain research in Canada. For more than one decade, Brain Canada has made the case for the brain as a single, complex system with commonalities across the range of neurological disorders, mental illnesses and addictions, brain and spinal cord injuries. Looking at the brain as one system has underscored the need for increased collaboration across disciplines and institutions, and a smarter way to invest in brain research that is focused on outcomes that will benefit patients and families.
The Canadian Glycomics Network (GlycoNet) is a pan-Canadian initiative bringing together 140 researchers from 30 post-secondary institutions, as well as numerous industry and academic partners, who work together to develop solutions to unmet health needs through the study of glycomics. Glycomics-based research has the potential to lead to the development of new drugs, vaccines, and diagnostics for conditions such as cancer, genetic diseases or diabetes.
The network builds on Canada’s international leadership in glycomics over the last 50 years. By bringing together all key Canadian glycomics researchers and clinicians and offering unique core services, the network aims to become a global one-stop destination for researchers and industry seeking solutions to health issues through applied glycomics research. GlycoNet focuses on 5 research themes: antimicrobials, rare genetic diseases, diabetes and obesity, chronic disease, and therapeutic proteins and vaccines.
Accredited as a World Class Competitiveness Cluster in 2005, Lyonbiopole, a center of excellence for vaccines and diagnostics based in Lyon, focuses on the fight against human and animal infectious diseases and cancers. It aims to increase the competitiveness of the healthcare companies and the appeal of the Rhone-Alpes region territory, namely in the Lyon-Grenoble area. As an intermediary between the public and private sectors, the cluster works to encourage collaboration in R&D, to assist in the project building, to seek funding, to increase strategic and financial partnerships for the economic and international development of companies, and to provide access to project hosting facilities and shared technological platforms such as Lyonbiopole’s Infectious Diseases Center, which opened on 1 April 2009.
MaRS Innovation (MI) is the commercialization agent for the exceptional discovery pipeline from 16 leading Ontario academic institutions. As a single-entry point to total member research activity of $1B in annual research and development, MI provides an easy gateway for investors and licensees who wish to gain access to technology assets in Ontario. Supported by the Government of Canada through the Networks of Centres of Excellence, by the Government of Ontario through the Ontario Centres of Excellence, and by its member institutions, MI is a transformational partnership that turns research strengths into real commercial opportunities. MI’s portfolio includes the most promising assets and advances commercialization into global markets through industry partnerships, licensing and company creation.
The Massachusetts Life Sciences Center (MLSC) is a quasi-public agency of the Commonwealth of Massachusetts tasked with implementing the Massachusetts Life Sciences Act, a 10-year, $1-billion initiative that was signed into law in June of 2008. The MLSC’s mission is to create jobs in the life sciences and support vital scientific research that will improve the human condition. This work includes making financial investments in public and private institutions that are advancing life sciences research, development and commercialization as well as building ties among sectors of the Massachusetts life sciences community.
Through unique research and training programs, Mitacs is developing the next generation of innovators with vital scientific and business skills. In partnership with companies, government and academia, Mitacs is supporting a new economy using Canada’s most valuable resource – its people.
*Mitacs is a national, not-for-profit research organization.
The Oncopole is a Quebec hub for research, development and investment to accelerate the fight against cancer. Created in February 2017, it is the outcome of a unique co-creation process led by the Fonds de recherche du Québec – Santé (FRQS) and made possible by an initial $15M investment from Merck Canada. The Oncopole’s mission is to act as a catalyst leveraging actions made by key players in the Quebec’s oncology and innovation research ecosystem. It aims to position the province as a leader in the field. Its priorities, namely research, entrepreneurship, commercialization and integration of innovation, as well as clinical relevance, are orchestrated in order to foster stakeholder’s mobilization, the discovery of innovative approaches to fight cancer and, ultimately, a positive impact for the benefit of patients.
The Ontario Brain Institute is a provincially‐funded, not‐for‐profit research centre seeking to maximize the impact of neuroscience and establish Ontario as a world leader in brain research, commercialization and care. Convergent partnerships are created between researchers, clinicians, industry, patients, and their advocates to foster discovery and deliver innovative products and services that improve the lives of those living with brain disorders.
ZIM (Zentrales Innovationsprogramm Mittelstand / Central Innovation Program for SMEs) is a funding program from the German Federal Ministry for Economic Affairs and Energy (BMWi) intended to small and medium-sized enterprises (SMEs) with business operations in Germany that want to develop new or significantly improve existing products, processes or technical services. Public and private non-profit research and technology organizations (RTOs) acting as cooperation partners for a SME are also eligible for ZIM-funding. The goal of ZIM is to sustainably increase the innovative capacity and competitiveness of SMEs including craft businesses and independent professions. Thus the program contributes to the economic growth and creation of new jobs. It offers many funding opportunities among which the COOP program for cooperative R&D projects between SMEs or SMEs and RTOs. AiF Projekt GmbH, project management agency of BMWi, is in charge of the ZIM cooperation projects.